Figures & data
Table 1 Clinical characteristics of all PTCL patients
Table 2 Response evaluated at the end of primary treatmenta
Figure 1 Progression-free survival (PFS) for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) regimen.
![Figure 1 Progression-free survival (PFS) for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) regimen.](/cms/asset/4f64a9dc-0d4e-4e71-814f-c4ca1a2a4779/yhem_a_1152084_f0001_c.jpg)
Figure 2 Overall survival (OS) for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) regimen.
![Figure 2 Overall survival (OS) for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) regimen.](/cms/asset/d3388717-0ccd-4b13-a863-be6980715863/yhem_a_1152084_f0002_c.jpg)